Linked Life Data

15020292

Source:http://linkedlifedata.com/resource/pubmed/id/15020292

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2004-5-26
pubmed:abstractText
Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50%) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of LPS-mediated microvascular permeability and inflammation with marked increases in parameters of lung injury at both 6 and 24 hours after intratracheal LPS. Each parameter assessed was significantly reduced by intravenous S1P (1 microM final) and in selected experiments by the S1P analogue FTY720 (0.1 mg/kg, intraperitoneally) delivered 1 hour after LPS. S1P produced an approximately 40-50% reduction in LPS-mediated extravasation of Evans blue dye albumin, bronchoalveolar lavage protein content, and lung tissue myeloperoxidase activity (reflecting phagocyte infiltration). Consistent with systemic barrier enhancement, S1P significantly decreased Evans blue dye albumin extravasation and myeloperoxidase content in renal tissues of LPS-treated mice. These studies indicate that S1P significantly decreases pulmonary/renal vascular leakage and inflammation in a murine model of LPS-mediated acute lung injury and may represent a novel therapeutic strategy for vascular barrier dysfunction.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1073-449X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
169
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1245-51
pubmed:dateRevised
2008-6-5
pubmed:meshHeading
pubmed-meshheading:15020292-Animals, pubmed-meshheading:15020292-Bronchoalveolar Lavage Fluid, pubmed-meshheading:15020292-Capillary Permeability, pubmed-meshheading:15020292-Disease Models, Animal, pubmed-meshheading:15020292-Endothelial Cells, pubmed-meshheading:15020292-Endotoxins, pubmed-meshheading:15020292-Immunosuppressive Agents, pubmed-meshheading:15020292-Kidney, pubmed-meshheading:15020292-Kidney Diseases, pubmed-meshheading:15020292-Lipopolysaccharides, pubmed-meshheading:15020292-Lung, pubmed-meshheading:15020292-Lysophospholipids, pubmed-meshheading:15020292-Male, pubmed-meshheading:15020292-Mice, pubmed-meshheading:15020292-Mice, Inbred C57BL, pubmed-meshheading:15020292-Neutrophils, pubmed-meshheading:15020292-Organ Size, pubmed-meshheading:15020292-Perfusion, pubmed-meshheading:15020292-Peroxidase, pubmed-meshheading:15020292-Pneumonia, pubmed-meshheading:15020292-Propylene Glycols, pubmed-meshheading:15020292-Respiratory Distress Syndrome, Adult, pubmed-meshheading:15020292-Sphingosine, pubmed-meshheading:15020292-Time Factors
pubmed:year
2004
pubmed:articleTitle
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury.
pubmed:affiliation
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S.